| [1] |
Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74(2): 1014-1048.
|
| [2] |
Jothimani D, Rela M, Kamath PS. Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?[J]. Med Clin North Am, 2023, 107(3): 491-504.
|
| [3] |
Albillos A, Krag A. Beta-blockers in the era of precision medicine in patients with cirrhosis[J]. J Hepatol, 2023, 78(4): 866-872.
|
| [4] |
Turco L, Reiberger T, Vitale G, et al. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension[J]. Liver Int, 2023, 43(6): 1183-1194.
|
| [5] |
Xu X, Gao F, Wang T, et al. Association of non-selective β blockers with the development of renal dysfunction in liver cirrhosis: a systematic review and meta-analysis[J]. Ann Med, 2024, 56(1): 2305935.
|
| [6] |
Albillos A, Zamora J, Martínez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis[J]. Hepatology, 2017, 66(4): 1219-1231.
|
| [7] |
Cromer M, Wilcox CM, and Shoreibah M. Beta-blockers and cirrhosis: Striking the right balance[J]. Am J Med Sci, 2024, 367(4): 228-234.
|
| [8] |
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(18): e876-e894.
|
| [9] |
Jang YO, Kim SH, Cho MY, et al. Synergistic effects of simvastatin and bone marrow-derived mesenchymal stem cells on hepatic fibrosis[J]. Biochem Biophys Res Commun, 2018, 497(1): 264-271.
|
| [10] |
Motawi TM, Atta HM, Sadik NA, et al. The therapeutic effects of bone marrow-derived mesenchymal stem cells and simvastatin in a rat model of liver fibrosis[J]. Cell Biochem Biophys, 2014, 68(1): 111-125.
|
| [11] |
Marrone G, Maeso-Díaz R, García-Cardena G, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins[J]. Gut, 2015, 64(9): 1434-1443.
|
| [12] |
Wang W, Zhao C, Zhou J, et al. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis[J]. PLoS One, 2013, 8(10): e76538.
|
| [13] |
中华医学会外科学分会脾及门静脉高压外科学组, 杨连粤, 白雪莉. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2025版)[J]. 中国实用外科杂志, 2025, 45(3): 249-256.
|
| [14] |
Alvarado-Tapias E, Brujats A, Puente A, et al. Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized-trial[J]. Hepatology, 2025, 82(1): 140-154.
|
| [15] |
Wani ZA, Mohapatra S, Khan AA, et al. Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension[J]. World J Hepatol, 2017, 9(5): 270-277.
|
| [16] |
Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J]. N Engl J Med, 2005, 353(21): 2254-2261.
|
| [17] |
de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974.
|
| [18] |
Pollo-Flores P, Soldan M, Santos UC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial[J]. Dig Liver Dis, 2015, 47(11): 957-963.
|
| [19] |
Abraldes JG, Villanueva C, Aracil C, et al. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis[J]. Gastroenterology, 2016, 150(5): 1160-1170. e3.
|
| [20] |
Gratacós-Ginès J and Pose E. Review of the role of statins in cirrhosis and portal hypertension[J]. Clin Liver Dis(Hoboken), 2023, 22(2): 50-57.
|
| [21] |
Zhou XD, Kim SU, Yip TC, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease[J]. Gut, 2024, 73(11): 1883-1892.
|
| [22] |
Mohanty A, Tate JP, and Garcia-Tsao G. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis[J]. Gastroenterology, 2016, 150(2): 430-440. e1.
|
| [23] |
Huang YW, Lee CL, Yang SS, et al. Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study[J]. Am J Gastroenterol, 2016, 111(7): 976-85.
|
| [24] |
Simon TG, Bonilla H, Yan P, et al. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES[J]. Hepatology, 2016, 64(1): 47-57.
|
| [25] |
Chang FM, Wang YP, Lang HC, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study[J]. Hepatology, 2017, 66(3): 896-907.
|
| [26] |
Moctezuma-Velázquez C, Abraldes JG. How strong is the evidence to support statins repurposing for the treatment of cirrhosis?[J]. Rev Esp Enferm Dig, 2023, 115(3): 107-109.
|
| [27] |
Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study[J]. Dig Dis Sci, 2024, 59(8): 1958-1965.
|
| [28] |
Bang UC, Benfield T, and Bendtsen F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study[J]. Aliment Pharmacol Ther, 2017, 46(7): 673-680.
|
| [29] |
Motzkus-Feagans C, Pakyz AL, Ratliff SM, et al. Statin use and infections in Veterans with cirrhosis[J]. Aliment Pharmacol Ther, 2013, 38(6): 611-618.
|
| [30] |
Kumar A. Statin Exposure is Associated with Reduced Development of Acute-on-chronic Liver Failure in a Veterans Affairs Cohort[J]. J Clin Exp Hepatol, 2022, 12(6): 1572-1573.
|
| [31] |
Pose E, Solà E, Lozano JJ, et al. Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis[J]. Hepatol Commun, 2022, 6(5): 1100-1112.
|
| [32] |
Chapin S, Kaplan DE, Taddei T, et al. Association between statin exposure and short-term mortality in patients with high-grade acute-on-chronic liver failure[J]. JHEP Rep, 2023, 5(6): 100740.
|
| [33] |
Toh MR, Wong EYT, Wong SH, et al. Global Epidemiology and Genetics of Hepatocellular Carcinoma[J]. Gastroenterology, 2023, 164(5): 766-782.
|
| [34] |
Sharpton SR and Loomba R. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC[J]. Hepatology, 2023. 78(6): 1896-1906.
|
| [35] |
Liu C, Chen H, Hu B, et al. New insights into the therapeutic potentials of statins in cancer[J]. Front Pharmacol, 2023. 14: 1188926.
|
| [36] |
Cappuyns S, Corbett V, Yarchoan M, et al. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review[J]. JAMA Oncol, 2024, 10(3): 395-404.
|
| [37] |
Sung S, Al-Karaghouli M, Kalainy S, et al. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis[J]. BMC Gastroenterol, 2021, 21(1): 120.
|
| [38] |
Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis[J]. Gastroenterology, 2013, 144(2): 323-332.
|
| [39] |
Shi M, Zheng H, Nie B, et al. Statin use and risk of liver cancer: an update meta-analysis[J]. BMJ Open, 2014, 4(9): e005399.
|
| [40] |
Zhou YY, Zhu GQ, Wang Y, et al. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma[J]. Oncotarget, 2016, 7(16): 21753-21762.
|
| [41] |
Islam MM, Poly TN, Walther BA, et al. Statin Use and the Risk of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies[J]. Cancers(Basel), 2020, 12(3).
|
| [42] |
Kezer CA, Schmidt KA, Shah VH. Statin the course: Navigating unchartered territory in cirrhosis[J]. Hepatol Commun, 2024, 8(6).
|
| [43] |
Pose E, Napoleone L, Amin A, et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE- SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(1): 31-41.
|
| [44] |
Abraldes JG, Albillos A, Bañares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial[J]. Gastroenterology, 2009, 136(5): 1651-1658.
|
| [45] |
Bishnu S, Ahammed SM, Sarkar A, et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study[J]. Eur J Gastroenterol Hepatol, 2018, 30(1): 54-59
|